Advancing the precision oncology agenda in the EU Brussels, Belgium
13.11.24 - 13.11.24
Advancing the precision oncology agenda in the EU
As the European Union enters a new mandate, with fresh leadership defining future legislative and policy directions, there is an urgent need to prioritise the development of more innovative and resilient healthcare systems across Europe.
As the European Union enters a new mandate, with fresh leadership defining future legislative and policy directions, there is an urgent need to prioritise the development of more innovative and resilient healthcare systems across Europe. A key aspect of this development is the provision of personalised treatments for cancer patients so that healthcare solutions are tailored to individual needs.
The discussions will bring together various stakeholders such as policymakers, regional health authorities, patient advocates, and healthcare providers. Through an exchange on the opportunities for health systems and the tangible benefits for patients, as well as an exploration of the challenges in translating research into practical solutions, the event will spotlight successful EU initiatives and regional approaches to uptake precision oncology.
Register here.
Agenda:
|
08:00 – 09:00 |
Registration and coffee |
| 09:00 – 09:30 |
Welcome and opening remarks – setting the scene: realising the promise of personalised care for cancer and navigating precision medicine in oncology: opportunities and gains for health systems and for patients Dorota Tomalak: Deputy Head of Unit at the Committee of the Region’s NAT Commission secretariat Merel Hennink: lung cancer patient testimony of lived experience Dr. Nicola Normanno: Scientific Director, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Matthijs van Meerveld: EFPIA Oncology Platform, AVP & Global Head of Access Policy & Patient Advocacy, Oncology at Menarini Stemline |
| 09:30 – 10:00 |
EU policy leadership: driving precision oncology across Europe from research to policy implementation Moderated by Eduardo Pisani, All.Can Europe CEO, and Senior Counsel at Incisive Health Kay Duggan-Walls: Policy Officer, Seconded National Expert Raluca Painter: Head of Unit, Labour Market, Education, Health & Social Szymon Bielecki: Team Leader - EU policies, Unit H.3., eHealth, Well-Being and Ageing, DG CONNECT |
| 10:00 – 10:40 |
Collaborative excellence: EU initiatives paving the way for precision oncology Moderated by Eduardo Pisani, All.Can Europe CEO, and Senior Counsel at Incisive Health Implementing personalised medicine approaches - Jolien Roovers: partner in EP PerMed, leading the work on accelerating innovation on personalised medicine; Policy Advisor, Flemish government, Department Economy, Science & Innovation, Research Department Cancer diagnostics and treatment for all: Implementing NGS based and liquid biopsy assays in clinical practice – Marc van den Bulcke: Project Coordinator CAN.Heal, Sciensano Personalised cancer medicine for all EU citizens biopsy assays in clinical practice – Prof. Hans Gelderblom: Coordinator PCM4EU; Professor Internal Medicine, in particular medical oncology, Leiden University Fostering a network of experts on genomic testing - Hélène Antoine-Poirel, MD PhD: Cancer Centre Epidemiology and public health, Sciensano, JANE |
| 10:40 – 11:00 |
Coffee Break |
| 11:00 – 11:20 |
Implementing precision oncology across European regions: regional champions and success stories Moderated by Michele Calabrò, Director, EUREGHA Creating an optimal cancer care ecosystem – Alina Capitanu: Vice President of IMAGO-MOL Cluster on behalf of the North-East Regional Development Agency, MEDIC-NEST META-CLUSTER IN PRECISION MEDICINE project Implementing PO: Supporting implementation in cancer care - Mr. Robert Fabregat I Fuenters: PRECISEU, Project coordinator, Director of Biocat |
| 11:20 – 12:20 |
Pathways to access: overcoming financial barriers in precision oncology Moderated by Eduardo Pisani, All.Can Europe CEO, and Senior Counsel at Incisive Health The economics and funding of personalised care - dr. Frederick Thielen: HEcoPerMed, Assistant professor, Health Technology Assessment (HTA), Erasmus School of Health Policy & Management, Erasmus University Rotterdam Patient expectations and equitable access – Antonella Cardone: CEO, Cancer Patients Europe Perspective of the industry - Ivana Cattaneo: EFPIA Oncology Platform, Executive Director, Therapeutic Area Advocacy and Precision Medicine, Novartis Inequalities Register and Personalized Care – Richard Price: Head of Policy, European Cancer Organisation |
| 12:20 – 12:30 |
Closing remarks – a call to action |